About Kailera Therapeutics, Inc.
Developing therapies for obesity to empower people to transform their lives.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Founded
- 2024
- Company type
- Privately Held
- Company profile name
- Kailera Therapeutics
Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive clinical trial results in obesity in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com.
Business areas
- Biotechnology
- Pharmaceutical
- Therapeutics
On LinkedIn
- Followers
- 16,020
- People linked to this company
- 174
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
1,000,000,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.